Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055697 | 0.91 | SLC6A9 (0.65) | SLC6A9HPGDKMT2AP2RX7NPC1 | |
| SCHEMBL8279714 | 0.84 | SLC6A9 (0.70) | SLC6A9HPGDKMT2ANPC1LMNA | |
| SCHEMBL13037353 | 0.83 | SLC6A9 (0.64) | SLC6A9HPGDKMT2AP2RX7NPC1 | |
| SCHEMBL8240377 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL8244583 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL3042562 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL3059780 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL3561480 | 0.80 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL3560048 | 0.79 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL3558597 | 0.79 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | SLC6A9 18/4885HPGD 2932/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.